Viatris Inc

Viatris Inc. reported Q2 2026 net sales of $3.75 billion, an increase from $3.57 billion in the prior year quarter, but recorded a net loss of $118.8 million, widening from a $4.6 million loss in Q2 2025. However, year-to-date net earnings significantly improved to $57.6 million compared to a $3.05 billion loss in the same period last year, largely due to the absence of a goodwill impairment charge. The company also announced an agreement to sell Tyrvaya® product rights for $30 million upfront, resulting in a $177.8 million intangible asset write-down, and continued to reduce long-term debt to $11.61 billion.

Viatris Inc. reported second-quarter 2026 financial results, with Total Revenues reaching $3.8 billion, a 5% reported increase, and Adjusted EBITDA growing 10% to $1.2 billion. The company recorded a U.S. GAAP net loss of $119 million, primarily due to a non-cash charge related to the sale of Tyrvaya® rights. Viatris raised the midpoints of its 2026 financial guidance for all metrics, including Total Revenues and Adjusted EBITDA, and announced strategic divestments and capital returns to shareholders.

Viatris Inc. has entered into an amended and restated term loan credit agreement for ¥40,000,000,000 (approximately $250 million USD) with Mizuho Bank, Ltd. as the administrative agent. The proceeds from this new facility will be used to repay outstanding obligations under a previous ¥40 billion unsecured term loan facility and for general corporate purposes. The loan bears an initial interest rate of TIBO Rate plus 1.10% per annum and matures three years from the closing date of July 1, 2026. The agreement includes customary covenants, such as a financial covenant requiring a leverage ratio no greater than 3.75 to 1.00.

Viatris Inc. announced the completion of a public offering of 650 million aggregate principal amount of its 4.250% Senior Notes due 2033. The company intends to use the net proceeds primarily to repay the entire $1.675 billion outstanding principal amount of its 3.950% Senior Notes due 2026. Any remaining funds will be used to replenish cash for general corporate purposes.

Viatris Inc. announced it has entered into an underwriting agreement to issue and sell 650,000,000 principal amount of its 4.250% Senior Notes due 2033. The offering is being made pursuant to a Registration Statement on Form S-3 and a Prospectus Supplement dated June 12, 2026. The transaction is expected to close on June 17, 2026, subject to customary closing conditions.

Viatris Inc. reported a significant turnaround in its first quarter 2026 financial results, achieving net earnings of $176.4 million compared to a substantial net loss in the prior year, primarily due to the absence of goodwill impairment. Net sales increased to $3.51 billion, driven by growth in Developed Markets and Greater China. The company also declared a quarterly cash dividend of $0.12 per share.

Viatris Inc. reported strong first-quarter 2026 financial results, with total revenues reaching $3.5 billion, an 8% reported increase year-over-year, and U.S. GAAP net earnings of $176 million. The company also achieved $1.0 billion in Adjusted EBITDA, up 10% operationally. Viatris reaffirmed its full-year 2026 financial guidance and highlighted progress in key product launches and pipeline milestones, including the launch of Effexor® in Japan.

Viatris Inc. announced that Chief Financial Officer Theodora Mistras will depart the company effective May 8, 2026, to pursue another professional opportunity. Her resignation was not related to any disagreements regarding the company's financial practices. Paul Campbell, Viatris' current Chief Accounting Officer and Corporate Controller, has been appointed interim Chief Financial Officer, effective May 8, 2026, while the company searches for a permanent successor. Ms. Mistras will remain with the company until May 22, 2026, to ensure a smooth transition.